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Two recently completed phase 3 trials (003 and 004) showed ﬁdaxomicin to be noninferior to vancomycin for
curing Clostridium difﬁcile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults
with active CDI were randomized to receive blinded ﬁdaxomicin 200 mg twice daily or vancomycin 125 mg 4
times a day for 10 days. Post hoc exploratory intent-to-treat (ITT) time-to-event analyses were undertaken on
the combined study 003 and 004 data, using ﬁxed-effects meta-analysis and Cox regression models. ITT analy-
sis of the combined 003/004 data for 1164 patients showed that ﬁdaxomicin reduced persistent diarrhea, re-
currence, or death by 40% (95% conﬁdence interval [CI], 26%–51%; P < .0001) compared with vancomycin
through day 40. A 37% (95% CI, 2%–60%; P = .037) reduction in persistent diarrhea or death was evident
through day 12 (heterogeneity P = .50 vs 13–40 days), driven by 7 (1.2%) ﬁdaxomicin versus 17 (2.9%) vanco-
mycin deaths at <12 days. Low albumin level, low eosinophil count, and CDI treatment preenrollment were
risk factors for persistent diarrhea or death at 12 days, and CDI in the previous 3 months was a risk factor for
recurrence (all P < .01). Fidaxomicin has the potential to substantially improve outcomes from CDI.
Clostridium difﬁcile infection (CDI), mainly precipitated
by antibiotic treatment, has become an increasingly
severe healthcare-associated infection with markedly
changed epidemiology during the past decade [1]. The
emergence of a hypervirulent lineage (North American
pulsed-ﬁeld gel electrophoresis type 1 [NAP1]/restriction
endonuclease analysis type BI [BI]/polymerase chain
reaction [PCR] ribotype 027 [027]) led to steep increases
in incidence, causing epidemics in hospitals [1–3], a
higher proportion of severe disease [2, 3], reduced re-
sponse to metronidazole treatment [4–6], and higher
mortality [3, 5]. These features were ﬁrst evident in
North America but became prominent in Europe
shortly thereafter. CDI prevention programs have
become an intense focus for hospitals, with some evi-
dence of success [7]. However, CDI treatment is an
ongoing challenge as up to 20% of cases fail on currently
recommended treatment with oral metronidazole or
vancomycin (the only US Food and Drug Administra-
tion [FDA]–licensed therapy) [6, 8, 9]. More troubling is
the high proportion of patients (20%–30%) who relapse
after treatment, some repeatedly [10].
Fidaxomicin is a ﬁrst-in-class macrocyclic antibiotic
with advantages over other drugs used to treat CDI [11]
Correspondence: D. W. Crook, Microbiology Level 7, John Radcliffe Hospital,
Oxford, OX3 9DU, UK (derrick.crook@ndcls.ox.ac.uk).
Clinical Infectious Diseases 2012;55(S2):S93–103
© The Author 2012. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please email:
journals.permissions@oup.com. This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.
DOI: 10.1093/cid/cis499
Fidaxomicin vs Vancomycin in C. difﬁcile • CID 2012:55 (Suppl 2) • S93







and thus the potential to improve CDI treatment. It is more
active in vitro against C. difﬁcile strains including NAP1/BI/
027, has little activity for inhibiting other bowel ﬂora species
(both in vitro and in vivo), and achieves very high fecal concen-
trations with minimal systemic absorption [11–16]. Fidaxomi-
cin has been evaluated in 2 large double-blind randomized
noninferiority trials (studies 003 and 004), as required for li-
censing. The ﬁrst trial (study 003) showed ﬁdaxomicin to be
noninferior to vancomycin for cure in 629 participants, but
with signiﬁcantly lower recurrence rates than vancomycin for
non-NAP1/BI/027 strains [17]. The second trial (004) investi-
gating 535 patients has been recently reported and shows
similar results [18].
Combining the data from both studies provides an opportu-
nity to undertake post hoc intent-to-treat (ITT) time-to-event
exploratory analyses with increased power, particularly with
regard to early treatment effects, differences in treatment
effects between subgroups on different outcomes, and an in-
vestigation of risk factors.
METHODS
Study Design
Both prospective, multicenter, double-blind, randomized, parallel-
group trials followed the same protocol and were conducted in
accordance with the principles of the Declaration of Helsinki and
Good Clinical Practice. Both study protocols and amendments
were approved by institutional review boards at all centers.
Study 003 recruited from 62 sites (United States and
Canada), and study 004, from 86 sites (41 from the United
States and Canada and 45 from 7 European countries). In both
studies, participants were eligible if they were aged ≥16 years
with CDI deﬁned as diarrhea with >3 unformed stools in the
24 hours before randomization and C. difﬁcile toxin A, B, or
both detected in stool. Participants could have received up to 4
doses, but no more than 24 hours of treatment, of vancomycin
or metronidazole before randomization. Participants were ex-
cluded if they received other CDI-active antibiotics (eg, oral
bacitracin, fusidic acid, or rifaximin), presented with fulminant
disease (eg, toxic megacolon), and had known inﬂammatory
bowel disease, >1 CDI episode in the previous 3 months, or
previous exposure to ﬁdaxomicin. (See [17] supplement for
further exclusion criteria.) Microbiological testing for C. difﬁcile
toxin was performed at individual study sites according to their
own certiﬁed testing procedures (mostly enzyme immunoassay
[EIA] tests). A rapid EIA test (Meridian Bioscience, Inc, Cin-
cinnati, Ohio) was provided by the trial; in sites where this was
used, all results were conﬁrmed by the standard laboratory test.
Stools were cultured and typed as previously described [17].
After providing informed consent, participants were ran-
domized to receive 10 days’ oral therapy as either 200 mg of
ﬁdaxomicin every 12 hours with intervening matching doses
of placebo or 125 mg of vancomycin every 6 hours. Capsules
containing drug or placebo were indistinguishable. Randomi-
zation was stratiﬁed according to whether the current CDI was
a ﬁrst (primary infection) or second (ﬁrst recurrence) episode
within the 3 months before enrollment and by study site.
Clinical cure was deﬁned as resolution of diarrhea (≤3 un-
formed stools for 2 consecutive days) maintained for the subse-
quent duration of therapy with no further requirement for CDI
therapy assessed 2 days after the end of the 10-day blinded treat-
ment course (the primary posttreatment assessment). Clinical
failure was deﬁned as the persistence of diarrhea, need for addi-
tional CDI therapy, or both. Participants meeting criteria for clin-
ical cure were followed up for 28 days after the end of treatment
for a ﬁnal trial assessment (36–40 days after randomization).
Global cure was deﬁned as clinical cure without subsequent recur-
rence, with subsequent CDI recurrence deﬁned as the reappear-
ance of >3 unformed stools in any 24-hour period with C. difﬁcile
toxin A or B (or both) detected and a need for CDI retreatment,
and prompting a full trial assessment. “Global cure” is identical to
“sustained response” as deﬁned by the FDA.
The primary efﬁcacy endpoint was clinical cure in the mod-
iﬁed ITT (mITT) and per-protocol populations at the end-of-
therapy assessment as previously described [17], with a 10%
noninferiority margin. Secondary efﬁcacy endpoints were CDI
recurrence and global cure as deﬁned previously. In all these
prespeciﬁed analyses, early withdrawals and deaths were
treated as failures (not successes). Safety was evaluated as de-
scribed for study 003; results were similar (not shown).
Statistical Analysis
The primary and secondary efﬁcacy endpoints in both studies
were analyzed according to a meta-analysis of these outcomes
using ﬁxed-effect models. The endpoints were presented as
the poor outcomes, namely, “no clinical cure” (converse of
clinical cure), “no global cure” (converse of global cure), and
“recurrence,” so that relative risks for ﬁdaxomicin versus van-
comycin of <1 consistently indicate reduced risk for poor
outcome with ﬁdaxomicin.
A post hoc exploratory time-to-event ITT analysis of the
composite endpoint persistent diarrhea (equivalent to no clin-
ical cure) or CDI recurrence or death was undertaken across
both studies. This differed from the mITT analysis by only (1)
including all randomized patients, censoring those who never
took a dose of trial medication at 0.5 days; (2) censoring pa-
tients who were last clinically assessed before 8 days following
the start of treatment, providing that they were not known to
have died subsequently before 40 days from randomization (in
which case their failure time was the date of death); (3) cen-
soring patients last seen <33 days after the start of treatment,
but cured at their posttreatment assessment as their last
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assessment (as the earliest posttreatment assessment occurred
at 8 days and the FDA recommends that to be assessed as sus-
tained response [global cure], patients should be followed up
for 25 days posttreatment); and (4) considering patients who
were last seen ≥33 days following treatment initiation, but
were cured, as cured (ie, censored) on day 40.
Subgroup analyses of persistent diarrhea, recurrence, or
death in the combined data were conducted for 6 baseline
factors considered in the original study 003 publication (mild
vs moderate vs severe disease [mild disease deﬁned as 4–5
unformed stools per day or white blood cell {WBC} count ≤12
000/μL; moderate disease, as 6–9 unformed stools per day or
WBC count of 12 001–15 000/μL; severe disease, as ≥10 un-
formed stools per day or WBC count ≥15 001/μL]), previous
versus no previous CDI (in the last 3 months), strain type
NAP1/BI/027 versus non-NAP1/BI/027, age <65 versus ≥65
years, inpatient versus outpatient status, and anti-CDI antibiot-
ics (metronidazole or vancomycin) in the previous 24 hours.
These were supplemented by 4 baseline biomarkers chosen to
reﬂect underlying disease mechanisms and major morbidities
(albumin <25 vs ≥25 g/L, WBC count ≤12 000 vs >12 000/μL,
creatinine ≤150 vs >150 μmol/L, and hemoglobin <100 vs
≥100 g/L). Biomarker categorizations were ﬁxed before analysis.
Last, backward selection (exit P = .1) was used to identify
independent baseline predictors of persistent diarrhea, recur-
rence, or death in the combined data using Cox proportional
hazards regression models. Factors considered were random-
ized group, all the factors considered for subgroup analyses as
described (treating biomarkers as continuous variables trun-
cated at the 1st and 99th percentiles to reduce the inﬂuence of
outliers), plus other continuous biomarkers with P < .1 on uni-
variate analysis (alkaline phosphatase, blood urea nitrogen
[BUN], calcium, cholesterol, chloride, eosinophils, lactate de-
hydrogenase, urate, neutrophils, lymphocytes, creatinine clear-
ance [estimated using the Cockcroft-Gault formula], sodium,
and potassium values), and categorical variables (sex, race,
and metronidazole failure); values for aspartate aminotransfer-
ase, alanine aminotransferase, bicarbonate, bilirubin, globulin,
glucose, monocytes, phosphate, triglycerides, and platelets
were not signiﬁcant (P > .1) on univariate analyses and were
not considered in backward elimination. Any factor with sig-
niﬁcant (P < .1) heterogeneity between effects in the ﬁrst 0–12
days subsequently was allowed to be included in the model
with this time interaction, as were any signiﬁcant interactions
with randomized groups (P < .1) on bivariate analyses.
RESULTS
Combined 003 and 004 Studies
A total of 1164 participants were enrolled in either study 003
or 004 [17, 18]: there was no evidence of heterogeneity in
the primary and secondary outcomes in either the mITT or
per-protocol populations (P > .3, Figure 1). Overall results also
demonstrated noninferiority of ﬁdaxomicin compared with
vancomycin for clinical cure and superiority of ﬁdaxomicin
over vancomycin for recurrence and global cure (P < .0001).
Figure 2 shows the Kaplan-Meier curve for persistent diar-
rhea, recurrence, or death. Of note, there was no evidence of
heterogeneity in treatment effect 0–12 versus 13–40 days after
randomization (P = .50), with a signiﬁcant advantage evident
for ﬁdaxomicin versus vancomycin even through 0–12 days
(hazard ratio [HR], 0.61 [95% CI, .39–.98]; P = .03), which was
maintained over days 13–40 (HR, 0.51 [95% CI, .39–.67];
P < .0001). In contrast to the mITT and per-protocol analyses,
the only patients who count as failures before 12 days in the
ITT analysis are deaths occurring within 12 days of randomiza-
tion, which occurred in 7 of 572 (1.2%) participants random-
ized to ﬁdaxomicin versus 17 of 592 (2.9%) randomized to
vancomycin (exact P = .06). The FDA requires that other par-
ticipants not assessed posttreatment (early withdrawals) be
treated as failures for licensing studies, even though this as-
sumption is not necessarily conservative for the treatment
effect [19–21]. A total of 55 of 592 (9.3%) vs 54 of 572 (9.4%)
participants in the ﬁdaxomicin versus vancomycin groups were
early withdrawals, respectively; stated reasons were adverse
events (16 vs 16), withdrawal by subject (12 vs 14), and no
reason stated (27 vs 24). In the ITT analysis, these events are
assumed to be uninformative with respect to the outcome. This
assumption is plausible given that (1) the median day of early
withdrawal was 3 (interquartile range [IQR], 2–5) before treat-
ment response would have been expected, (2) there is no evi-
dence that blinding was compromised, and (3) these events
occurred equally in both arms at a median of 3 (IQR, 2–6) and
3 (IQR, 2–5) days for ﬁdaxomicin and vancomycin, respective-
ly. However, as these early withdrawals are numerically greater
than the number of early deaths, counting them as failures in
the FDA analysis has the potential to obscure a possible, but
important, additional beneﬁt of ﬁdaxomicin on early deaths.
To explore the difference among the 3 analyses, Figure 3
compares the ITT analysis with the mITT and per-protocol
analyses of the combined studies using ﬁxed-effects meta-
analysis. Overall, ﬁdaxomicin reduced persistent diarrhea, re-
currence, or death by 40% (95% CI, 26%–51%; P < .0001) in
the ITT analysis, corresponding to a number needed to treat
of 7.9 (95% CI, 5.7–12.9) in favor of ﬁdaxomicin and similar
to effects on CDI recurrence in the mITT/per-protocol popu-
lations. However, in contrast, the ITT analysis estimated a
37% reduction in persistent diarrhea or death by day 12 (95%
CI, 2%–60%; P = .037), whereas mITT/per-protocol analyses
of clinical failure/cure (also assessed at day 12) suggested
smaller beneﬁts associated with ﬁdaxomicin that did not reach
statistical signiﬁcance (P = .40 and P = .33, respectively).
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Overall, through 40 days, we found no evidence that the bene-
ﬁts of ﬁdaxomicin over vancomycin varied according to
disease severity, prior history of CDI, previous anti-CDI anti-
biotics, inpatient/outpatient status, age, baseline albumin level,
or baseline creatinine level (P > .35; Figure 4). Beneﬁts associ-
ated with ﬁdaxomicin were signiﬁcantly greater in those with
non-BI/NAP1/PCR ribotype 027 strains (P = .04) and those
with baseline hemoglobin level ≥100 g/L (P = .03). There was
also a trend (P = .09) to somewhat greater beneﬁts in those
with WBC count ≤12 000/μL. However, of note, the data were
consistent with a 22% reduction in persistent or recurrent di-
arrhea or death in those with BI/NAP1/PCR ribotype 027
strains, which accounted for 292 of the 814 strains assayed
(36%). This did not reach statistical signiﬁcance within this
underpowered subgroup (95% CI, 44% reduction to 8%
increase; P = .14). There was no subgroup in which
ﬁdaxomicin performed more poorly than vancomycin.
Subgroup analyses restricting to the ﬁrst 12 days (persistent
diarrhea or death) showed similar results (Figure 5), except
that there was now no evidence that the beneﬁts associated
with ﬁdaxomicin varied according to strain type (P = .59) or
WBC count (P = .40). Greater beneﬁts from ﬁdaxomicin in
those with normal or mildly impaired hemoglobin versus
moderately/severely abnormal values persisted (P = .02).
Risk Factors
Independent predictors in the ﬁnal multivariate ITT model are
shown in Table 1: randomization to ﬁdaxomicin versus vanco-
mycin reduced the risk for persistent diarrhea, recurrence, or
death by 52% (95% CI, 37%–63%; P < .0001) even after adjust-
ment for other factors. Persistent diarrhea or death in the ﬁrst
Figure 1. Results of primary and secondary outcomes for studies 003 and 004. Individual results for each prespeciﬁed primary and secondary
outcome are presented for studies 003 and 004 separately and are combined using ﬁxed-effects meta-analysis in the modiﬁed intent-to-treat and per-
protocol populations. The primary endpoint Clinical Cure is shown as the converse No Clinical Cure, and the secondary endpoint Global Cure, as the
converse No Global Cure, so that relative risks for ﬁdaxomicin versus vancomycin of <1 consistently indicate reduced risk for poor outcome with
ﬁdaxomicin. Abbreviations: CI, conﬁdence interval; RR, relative risk.
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12 days was predicted most strongly by previous anti-CDI anti-
biotics in the 24 hours before randomization (P = .0001),
and low baseline eosinophil count (P = .007) and/or albumin
level (P < .0001) at randomization. Eosinophils and previous
antibiotic therapy had no effect on events from days 13–40 (re-
currence or death), but patients with low albumin levels at CDI
diagnosis remained at increased risk for recurrence or death.
Although there was no evidence that previous CDI in the last 3
months strongly affected persistent diarrhea/death in the ﬁrst
12 days, it was associated with a 68% higher risk for recurrence
or death (days 13–40). Patients with an elevated BUN level or
lower creatinine clearance at CDI diagnosis had slightly higher
risks for persisting diarrhea, recurrence, or death throughout
follow-up (days 0–40). In this multivariate model, there was no
evidence of increased risk for recurrence in patients with lower
hemoglobin levels receiving ﬁdaxomicin (P = .96). Strain
typing information was available for only 814 (70%) of the trial
participants’ isolates: effects of factors in Table 1 remained
similar in the subset with strain typing available. Although BI
strain per se was not associated with increased risk for persis-
tent diarrhea, recurrence, or death (HR, 1.07 vs non-BI strains
[95% CI, .73–1.56]; P = .73), the effect of ﬁdaxomicin versus
vancomycin remained larger in those with non-BI strains (HR
[ﬁdaxomicin:vancomycin], 0.30 [95% CI, .19–.46]) than BI
strains (HR, 0.78 [95% CI, .51–1.19]; heterogeneity P = .002),
as in the unadjusted analysis.
DISCUSSION
In the recently reported trials (studies 003 and 004) using
FDA-recommended mITT and per-protocol populations, ﬁ-
daxomicin was shown to be noninferior to vancomycin for
clinical cure, the primary prespeciﬁed endpoint [17, 18]. It
was also shown to be superior to vancomycin for the 2 sec-
ondary endpoints, recurrence and global cure.
The antimicrobial properties of ﬁdaxomicin have been
shown to have several advantages over vancomycin in a range
of settings. Fidaxomicin is bactericidal [11] and exhibits sub-
stantially higher inhibitory activity [12–16], has a more pro-
longed postantibiotic effect [22], and is narrower in spectrum
both in vitro [12–15] and in vivo [23, 24] than vancomycin [11],
which is bacteriostatic. This advantageous activity extended to
the BI/NAP1/PCR ribotype 027 strains in vitro [11]. The lack
of advantage of ﬁdaxomicin observed in the mITT and per-
protocol analyses of clinical cure was therefore disappointing.
To further explore the relative beneﬁts of ﬁdaxomicin versus
vancomycin, we conducted a post hoc exploratory time-to-
event analysis, following the ITT analysis strategy used most
commonly in nonlicensing trials.
This ITT analysis showed an overall 40% (95% CI, 26%–
51%; P < .0001) reduction in persistent diarrhea, recurrence, or
death during the 40-day follow-up. Interestingly, the ITT anal-
ysis through day 12 also showed a 37% (95% CI, 24%–60%;
Figure 2. Persistent diarrhea, recurrence, or death. Study treatment was administered for 10 days and clinical cure was assessed at 12 days, at
which time persistent diarrhea (>3 stools/24 hours and toxin A and/or B positive or requiring anti–Clostridium difﬁcile infection [CDI] treatment) was
deﬁned as clinical failure. The events occurring before day 12 are deaths and the step increase in events at day 12 represents cases assessed to have
persistent diarrhea at the posttreatment assessment. Events from day 13 to day 40 represent CDI recurrence or deaths. Abbreviation: HR, hazard ratio.
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P = .037) reduction in persistent diarrhea or death, which dif-
fered from the mITT or per-protocol analyses that suggested
smaller nonsigniﬁcant early beneﬁts of ﬁdaxomicin versus van-
comycin. Furthermore, there was no evidence of heterogeneity
between the beneﬁcial effects of ﬁdaxomicin prior to or after
day 12 in the ITT analysis, supporting a consistent advantage
for ﬁdaxomicin compared with vancomycin treatment both
early and late. Even though this beneﬁcial effect is biologically
plausible given the in vitro microbiological properties of ﬁdax-
omicin, the results from this post hoc exploratory analysis will
need to be separately conﬁrmed in further studies.
Subgroup analyses also supported beneﬁts for ﬁdaxomicin
over vancomycin across all subgroups other than severe
anemia (hemoglobin <100 g/L) or for BI/NAP1/PCR ribotype
027 strains, providing reassurance for its likely beneﬁt in wide-
spread clinical practice. There is no obvious mechanistic ex-
planation for the lack of effect in severe anemia, although the
fact that this interaction did not persist in a fully adjusted
multivariate model suggests that it could be a consequence of
confounding. In contrast, smaller beneﬁts among BI/NAP1/
PCR ribotype 027 strains were observed in subgroup analyses
and multivariate models. The nonsigniﬁcant beneﬁt of 22%
for persistent diarrhea, recurrence, or death observed for ﬁ-
daxomicin compared with vancomycin in these strains
contrasts with the clear beneﬁt evident for non-BI/NAP1/PCR
ribotype 027 strains. However, given that only 292 of the 814
strains assayed were BI/NAP1/PCR ribotype 027, even the
combined dataset is underpowered to conclude that ﬁdaxomi-
cin has no beneﬁcial effect for treating BI/NAP1/PCR ribotype
027 strains, which was suggested in the previously reported
mITT and per-protocol analyses [17]. The perils of concluding
lack of beneﬁt in underpowered subgroups of patients are well
recognized in the medical literature [25, 26].
The ITT analysis was used to investigate the independent
risk factors for outcomes using Cox regression. The overall
beneﬁt of ﬁdaxomicin compared with vancomycin was clearly
conﬁrmed, even after adjustment for other important predic-
tors. Previous vancomycin or metronidazole treatment in the
24 hours before randomization, low eosinophil count (<0.1 ×
109/L), and low albumin level were independent predictors of
persistent diarrhea or death in the ﬁrst 12 days. Previous anti-
CDI antibiotic treatment as deﬁned here is likely to be speciﬁc
to this trial design and may be an indication of cases with
more severe disease receiving empiric anti-CDI antibiotics
preenrollment. Low eosinophil count has not been observed as
a risk factor previously, although it may reﬂect immunosup-
pression associated with, for example, steroid treatment typical
of transplant or cancer patients who are recognized as being at
Figure 3. Comparison of intent-to-treat (ITT), modiﬁed ITT (mITT), and per-protocol analyses of the combined 003 and 004 study populations. For the
ITT analysis, persistent diarrhea or death refers to events occurring in the ﬁrst 12 days of the 40-day follow-up as in the time-to-event analysis depicted
for days 0–12 in the Kaplan-Meier curve. Persistent diarrhea, recurrence, or death refers to events occurring during the entire study period, days 0–40.
For the mITT and per-protocol analyses, No Clinical Cure refers to the converse of Clinical Cure assessed at day 12. No Global Cure refers to the
converse of Global Cure and included the 40-day follow-up. The converse of each endpoint is depicted so that relative risks for ﬁdaxomicin versus
vancomycin of <1 consistently indicate reduced risk of poor outcome with ﬁdaxomicin. Abbreviations: CI, conﬁdence interval; RR, relative risk.
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risk for a worse outcome from CDI in some [27], but not all [28],
studies. Low albumin level is a well-recognized predictor of
poorer outcome [28].
The only independent factor strongly associated with
longer-term recurrence or death (days 13–40) was a previous
episode of CDI in the preceding 3 months, consistent with
higher risks for second CDI recurrences in cases already expe-
riencing a ﬁrst recurrence [29]. Overall, a low calculated
creatinine clearance or elevated BUN level was independently
associated with a slightly higher risk for persistent diarrhea,
Figure 4. Subgroup analysis for persistent diarrhea, recurrence, or death through day 40. The results depicted are from the intent-to-treat analysis
and include events occurring from day 0 to day 40. Abbreviations: CDI, Clostridium difﬁcile infection; CI, conﬁdence interval; RR, relative risk.
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recurrence, or death. Elevated creatinine level in particular has
been previously reported as a risk factor for a poor outcome
[5, 28]. In contrast to other well-designed studies, having ad-
justed for these other factors, age and WBC count (including
neutrophil count) were not independently associated with
poor outcome [5, 26, 28], nor was disease severity at randomi-
zation. Lack of an independent effect of age in particular is
likely a consequence of baseline biomarkers lying on the
causal pathway between age and poorer outcome, in other
words, strong univariate associations between older age and
Figure 5. Persistent diarrhea or death through day 12. The results depicted are from the intent-to-treat analysis and include events occurring from day
0 to day 12. Abbreviations: CDI, Clostridium difﬁcile infection; CI, conﬁdence interval; RR, relative risk.
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poor outcome are explained by worse baseline biomarkers in
older patients.
In contrast to a recent report, the BI/NAP1/PCR ribotype
027 strain was not associated with a poor outcome [26], possi-
bly reﬂecting the inclusion of only a subset of patients with
better underlying health status in these randomized trials.
Although the associations found between baseline factors and
outcome within this subpopulation cannot be a consequence
of bias, whether our ﬁndings generalize to a wider patient
pool requires conﬁrmation in further studies.
In summary, data from the 2 licensing trials comparing
ﬁdaxomicin versus vancomycin suggest that this drug has the
potential to substantially improve outcomes from this impor-
tant healthcare-associated infection. Additional observational
studies as it becomes more widely used in clinical practice will
be important for further deﬁning its optimal use.
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Table 1. Independent Predictors of Persistent Diarrhea, Recurrence, or Death in the Intent-to-Treat Analysis
Factor
Univariate Model Multivariate Model
HR (95% CI) P Value HR (95% CI) P Value
Fidaxomicin vs vancomycin 0.54 (.42–.68) <.0001 0.48 (.37–.63) <.0001
Previous anti-CDI antibioticsa in the 24 hours
before randomization (yes vs no)
Failure/death 0–12 days 3.11 (1.95–4.97) <.0001 3.11 (1.75–5.52) .0001
Recurrence/death 13–40 days 1.24 (.95–1.62) .12 1.00 (.73–1.37) .99
het P= .001 het P= .001
Eosinophils (/0.1 × 109/L higher)
Failure/death 0–12 days 0.74 (.58–.94) .01 0.74 (.60–.92) .007
Recurrence/death 13–40 days 0.99 (.90–1.09) .78 0.98 (.89–1.07) .63
het P= .03 het P= .02
Albumin (/5 g/dL higher)
Failure/death 0–12 days 0.56 (.46–.68) <.0001 0.64 (.51–.79) <.0001
Recurrence/death 13–40 days 0.83 (.75–.92) .0003 0.87 (.78–.98) .02
het P= .0004 het P= .01
Previous CDI in last 3 months (yes vs no)
Failure/death 0–12 days 0.84 (.44–1.58) .58 0.61 (.29–1.28) .19
Recurrence/death 13–40 days 1.52 (1.11–2.09) .009 1.68 (1.19–2.37) .003
het P= .10 het P= .02
Creatinine clearance (/10 mL/min higher) 0.92 (.89–.94) <.0001 0.96 (.93–1.00) .05
BUN (/1 mg/dL higher) 1.06 (1.04–1.08) <.0001 1.03 (1.00–1.06) .04
All models stratified by study (003 or 004). Multivariate model fitted on 994 complete cases. No additional effect of severity (P = .64); inpatient versus outpatient
status (P = .65); age (P = .42); sex (P = .54); race (P = .43); metronidazole failure (P = .76); or alkaline phosphatase (P = .16), creatinine (P = .78), lactate
dehydrogenase (P = .12), urate (P = .15), hemoglobin (P = .80), neutrophils (P = .13), lymphocyte (P = .93), white blood cell count (P = .25), calcium (P = .56),
sodium (P = .91), potassium (P = .57), chloride (P = .82), and cholesterol levels (P = .64).
Abbreviations: BUN, blood urea nitrogen; CDI, Clostridium difficile infection; CI, confidence interval; het, heterogeneity; HR, hazard ratio; ITT, intent-to-treat.
a Anti-CDI antibiotics in this study were metronidazole and vancomycin.
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Optimer Study 003/004 teams. In addition to the authors, the follow-
ing investigators participated in the study: Humber River Regional Hospi-
tal, Toronto ON, M. Gerson; Mercury Street Medical Group, Butte MT,
J. Pullman; Idaho Falls Infectious Disease, PLLC, Idaho Falls, ID,
R. Nathan; Lakewood Hospital, Lakewood, OH, W. Riebel; Lakeridge
Health Center, Oshawa, ON, M. Silverman; Louis Stokes VA Medical
Center, Cleveland, OH, C. Donskey; Centre de Sante et des Services
Sociaux de Chicoutimi, Chicoutimi, QC, D. Grimard; Remington Davis
Inc, Columbus, OH, I. Baird; Missouri Baptist Medical Center, St Louis,
MO, M. J. Cox; Summa Health Systems, Akron, OH, M. Tan; Infectious
Diseases Minneapolis Ltd, Minneapolis, MN, C. Schrock; VA Long Beach
Healthcare System, Long Beach, CA, I. L. Gordon; Erie County Medical
Center, Buffalo, NY, C.-B. Hsiao; Southeast Alabama Medical Center,
Dothan, AL, J. C. Jones; Harper University Hospital, Detroit, MI,
G. Alangaden; St Joseph’s Healthcare, Hamilton, ON, C. Lee; University of
Minnesota, Minneapolis, MN, J-A. Young; Atlanta Institute for Medical
Research, Decatur, GA, A. Bressler; South Jersey Infectious Disease,
Somers Point, NJ, C. Lucasti; Jena, LA, R. M. Chaudhry; Royal University
Hospital, Saskatoon, SK, E. Larkai; Keego Harbor MIA, Markowitz;
Florida Research Network LLC, Gainesville, FL, R. G. Ashley; Morton
Plant Mease Health Care Inc, Clearwater, FL, J. Berner; University of
Maryland, Baltimore, MD, G. Bochicchio; Windsor Regional Hospital,
Windsor, ON, A. Dhar; Lowdermilk Clinical Research, Winston-Salem,
NC, T. Lowdermilk; Surrey Memorial Hospital, Surrey, BC, Y. Mirzanejad;
United Medical Research, New Smyrna Beach, FL, M. Nagrani; Stamford
Hospital, Stamford, CT, M. F. Parry; ID Clinical Research Ltd, Toledo,
OH, L. E. Jauregui-Peredo; DiGiovanna Family Care, N. Massapequa, NY,
M. DiGiovanna; Centre Hospitalier Universitaire de Quebec, Quebec City,
QC, C. Dallaire; University of Virginia Health System, Charlottesville, VA,
G. Donowitz; Lehigh Valley Mt Sinai Hospital, Toronto, ON, A. McGeer;
East Tennessee State University, Johnson City, TN, J. Moorman; Health
First Medical Group, Fort Worth, TX, M. Morrison; Cooper Hospital/Uni-
versity Medical Center, Camden, NJ, A. Reboli; Albany Medical Center
Hospital, Albany, NY, E. Tobin; Centre Hospitalier Universitaire de Sher-
brooke, Sherbrooke, QC, L. Valiquette; Christiana Care Health System,
Newark, DE, A. Bacon; Hotel-Dieu de Levis, Levis, QC, R. Bourdages; St
Vincent Catholic Medical Center, New York, NY, C. Carpati; Springﬁeld
Clinic, LLP, Springﬁeld, IL, D. Graham; Newark Beth Israel Medical
Center, Newark, NJ, T. Redling; Roswell Park Cancer Institute, Buffalo,
NY, N. Almyroudis; Midwest Infectious Disease Specialists, Naperville, IL,
J. Augustinsky; Bellam Medical Clinic, Dunnellon, FL, R. Bellam; Infec-
tious Disease Research of Indiana, Indianapolis, IN, C. Bunce; Humility of
Mary Health Partners, Youngstown, OH, A Hospital, Toronto, ON,
K. Katz; KMED Research, St Clair Shores, MI, C. Ketels; University of
Wisconsin, Madison, WI, D. Maki; Baystate Medical Center, Springﬁeld,
MA, P. C. Lee; AppleMed Research, Inc, Miami, FL, L. Perez-Limonte;
Tequesta Research Grou Clinical Trial Links LLC, Houston, TX,
K. Shivshonker; University Hospital Brugmann, Brussels, Belgium,
S. L. Chériﬁ; O. L. Vrouwziekenhuis, Belgium, I. Demeyer; UZ Gent,
Belgium, M. De Vos; Clinique Saint-Joseph, Liege, Belgium, F. Fontaine;
University Hospital Saint-Pierre, Brussels, Belgium, M. Gérard; University
Hospital Charleroi, Montigny-le-Tilleul, Belgium, P. Gruselle; ULB
Erasmus Hospital, Brussels, Belgium, F. Jacobs; AZ Sint-Lucas, Gent,
Belgium, A. Mast; Domaine Universitaire du Sart-Tilman, Liege, Belgium,
M. Moutschen; ZNA Middelheim, Antwerpen, Belgium, S. Naegels; Uni-
versity Hospital AmbroiseParé, Mons, Belgium, C. Rossi; AZ Groeninge-
Sint-Niklaas, Kortrijk, Belgium, P. Vergauwe; Raymond Poincaré Hospital,
Garches, France, L. Bernard; Hôpital Nord, Amiens, France, J.-L. Dupas;
Hôpital Gériatrique les Bateliers, Lille Cedex, France, F. Puisieux; Centre
Hospitalier Universitaire, Caen, France; Hôpital Dron Service des Maladies
Infectieuses et Tropicales, Tourcoing, France, E. Senneville; Hôpital
Michallon, Grenoble, France, J.-P. Stahl; Universitätsklinikum Schleswig-
Holstein, Lübeck, Germany, K. Dalhoff; Kliniken der Stadt Köln, Köln,
Germany, A. J. Dormann; Krankenhaus Porz am Rhein, Köln, Germany,
W. Holtmeier; Universitaetsklinikum Ulm, Ulm, Germany, P. Kern; Uni-
versitätsklinikum Magdeburg, Magdeburg, Germany, P. Malfertheiner;
Klinikum der Universität Regensburg, Regenburg, Germany, B. Salzberger;
Universitätsklinik Frankfurt, Frankfurt, Germany, S. Zeuzem; Universita
di Torino, Turin, Italy, G. Di Perri; Struttura Complessa de Malattie Infet-
tive, Busto Arsizio, Italy, T. Quirino; Hospital Geneal Universitario Gre-
gorio Marañón, Madrid, Spain, E. Bouza Santiago; Hospital Ramón y
Cajal, Madrid, Spain, J. Cobo Reinoso; Hospitales Universitarios Virgen
del Rocio, Sevilla, Spain, M. Herrero Romeroa; Hospital Clinic, Barcelona,
Spain, J. A. Martinez; Hospital Universitari Vall d’Hebron, Barcelona, Spain,
A. Pahissa Berga; Orebro University Hospital, Orebro, Sweden, E. Back; Sahl-
grenska University Hospital, Göteborg, Sweden, L. Hagberg; The Royal
Surrey County Hospital, Guildford, UK, A. Guyot; Barnsley Hospital NHS
FT, Barnsley, UK, K. Kapur; Brighton and Sussex University Hospitals NHS
Trust, Brighton, UK, M. Llewelyn; Nottingham University Hospitals NHS
Trust, Nottingham, UK, Y. Mahida; York Hospital, York, UK, S. J. Smale;
Horton General Hospital, Banbury, UK, A. Woodhouse; Cambridge Univer-
sity Hospitals NHS Foundation, Cambridge, UK, J. Woodward.
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